Breaking Update: Here’s a clear explanation of the latest developments related to Breaking News:Foslevodopa/Foscarbidopa (LDp/CDp): A Practical Guide to Optimising Continuous Infusion Therapy in Advanced Parkinson’s Disease– What Just Happened and why it matters right now.
This infographic has been sponsored by AbbVie.
This infographic is intended for healthcare professionals only. Prescribing information for foslevodopa/foscarbidopa can be found here. Adverse event reporting information can be found at the bottom of this page.
EMJ has published this infographic on behalf of AbbVie and has had no input into its creation.
It presents best practices for patient selection, treatment initiation, dose titration, and long-term management of 24-hour subcutaneous infusion therapy. Designed to support clinicians in delivering tailored, continuous dopaminergic therapy, the guide emphasises early follow-up, expectation setting, and nurse-led support to enhance treatment outcomes and adherence.